A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Clinical trial NCT05797610 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05797610
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-08
- Primary completion
- 2026-08-31
- Enrollment
- 459
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.